Participants
Crohn's disease or ulcerative colitis, neuropathy, Bone marrow dysplasia syndrome, prostate, half-body external beam radiation, fecal incontinence, Heart failure, prostate cancer
METASTASIS, NEUROPATHY, ADVERSE EVENTS, PROSTATE CANCER, BONE METASTASIS, PROSTATE, SPINAL CORD COMPRESSION, INFECTIOUS DISEASE, FECAL INCONTINENCE, ONCOLOGY, HEART FAILURE, HEART, METASTASES, PROSTATE CANCER
The following inclusion criteria will be used for this trial:Patients who have been diagnosed with prostate cancer either histologically or cytologically.Patients who have known castration resistance, defined as follows:Serum testosterone ≤ 50 ng/dL (1.7 nmol/L)Bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist or androgen deplevation therapy during the study periodA new or exacerbated lesion as seen on imaging.Patients with defined active metastases localized in one to three bones as seen on WB-DWI within the last three months. Active metastatic will be assessed based on MET-RADS-P (METastasis Reporting and Data System for Prostate Cancer), which proposes to standardize data interpretation and reporting of WB-DWI performed in men with advanced prostate cancer [Patients aged over 20 years.Patients whose Eastern Cooperative Oncology Group Performance Status(ECOG-PS) is 0 or 1.Patients with laboratory test values consistently meeting the following cutoffs:Absolute neutrophils ≥ 1.5 × 10Platelets ≥ 100 × 10Hemoglobin ≥ 10.0 g/dL (6.2 nmol/L). Total bilirubin ≤ 1.5 times upper limit of normal (ULN). Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times ULN. Creatinine ≤ 1.5 times ULN.Albumin ≥ 25 g/L. Corrected calcium ≥ 8.4 mg/dL.Patients who are willing and able to follow the study protocol for this study, including follow-up surveys and tests. Patients who provide written informed consent for this clinical study.The following exclusion criteria will be used for this trial:Patients who have received other research drugs within the past four weeks or who are planning to receive other research drugs during the research drug administration period.Patients who have received cytotoxic chemotherapy within the last three weeks or who are scheduled to receive cytotoxic chemotherapy during the study drug administration period, or patients who have not recovered from adverse events caused by cytotoxic chemotherapy given four or more weeks previously (excepting ongoing neuropathy, which is acceptable).Patients who have received half-body external beam radiation.Patients who have received systemic administration of radioactive isotopes of yttrium-90, lutetium-177, bismuth 213, strontium-89, samarium-153, rhenium-186, and rhenium-188 for the treatment of bone metastasis within the past 24 weeks. Patients who have been treated with radium-223.Patients who have received blood transfusion or erythropoietin administration within the past four weeks.Patients with organ metastasis, lymph node metastasis, or active lesion in the prostate detected by WB-DWI within the past three months.Patients who are in a state of urgency as indicated by clinical findings or MRI or patients who have obvious spinal cord compression.Patients with other serious illnesses or medical conditions such as, but not limited to: Poorly controlled infectious disease.Heart failure of grade III or IV according to the cardiac function classification established by the New York Heart Association Crohn's disease or ulcerative colitis. Bone marrow dysplasia syndrome.Patients with fecal incontinence that is difficult to manage.Patients expected to require the use of chemotherapy or androgen receptor axis-targeted therapy (ARAT) including enzalutamide, abiraterone acetate and prednisolone during administration of the research drug.Patients with a history of irradiation to the planned irradiation site of the target therapy.